A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 20, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Participants Less Than 12 Months of Age With RSV Illness
Interventions
BIOLOGICAL

Motavizumab

A single IM dose of 30 mg/kg will be administered on Day 0 of the study.

OTHER

Placebo

A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.

Trial Locations (31)

23298

Research Site, Richmond

25302

West Virginia University Pediactric Center, Charleston

26506

Research Site, Morgantown

30342

Research Site, Atlanta

30912

Research Site, Augusta

33606

Research Site, Tampa

44051

Research Site, Youngstown

48201

Research Site, Detroit

72202

Research Site, Little Rock

72205

Research Site, Charleston

72401

Research Site, Jonesboro

73104

Research Site, Oklahoma City

75230

Research Site, Dallas

75390

Research Site, Dallas

77030

Research Site, Houston

89107

Research Site, Las Vegas

92103

Research Site, San Diego

92868

Research Site, Orange

Unknown

Research Site, Tucson

Research Site, Jonesboro

Research Site, Little Rock

Research Site, Miami

Research Site, Chicago

Research Site, Baltimore

Research Site, The Bronx

02111

Research Site, Boston

07503

Research Site, Paterson

11203-2098

Research Site, Brooklyn

14222-2099

Research Site, Buffalo

37232-2581

Research Site, Nashville

25701-3655

Research Site, Huntington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00435227 - A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness | Biotech Hunter | Biotech Hunter